Engineered donor cells take aim at Hard-to-Treat cancers
NCT ID NCT07410494
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard treatments. Participants receive either a single-target or dual-target cell product, along with chemotherapy to prepare the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Donor-derived CAR-NK cells (engineered immune cells) with chemotherapy (fludarabine and cyclophosphamide) and IL-2
What this could lead to
If successful, this could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 85 participants, so results may not apply to everyone. Risks include side effects from chemotherapy and the CAR-NK cells, and the treatment may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
District One Hospital
RECRUITINGBeijing, Beijing Municipality, 086-373, China
Contact Phone: •••-•••-•••• Email: •••••@•••••